ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...

Legend Biotech (LEGN) has released an update. Legend Biotech’s CARVYKTI® has demonstrated a significant improvement in minimal residual disease negativity for multiple myeloma patients compared to ...

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, ...

In a retrospective cohort of patients with central nervous system manifestations of multiple myeloma, ide-cel CAR T-cell ...

Incidentally discovered vertebral fractures are common on scans in general population, but the absolute risk for MM in such ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.

Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey, shares long-term follow-up data on the efficacy ...